Taysha Gene Therapies, Inc. Annual Operating Income (Loss) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Taysha Gene Therapies, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2023.
  • Taysha Gene Therapies, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$25.9M, a 59.4% decline year-over-year.
  • Taysha Gene Therapies, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$87.8M, a 20.3% increase year-over-year.
  • Taysha Gene Therapies, Inc. annual Operating Income (Loss) for 2023 was -$72.4M, a 55.4% increase from 2022.
  • Taysha Gene Therapies, Inc. annual Operating Income (Loss) for 2022 was -$162M, a 6.25% increase from 2021.
  • Taysha Gene Therapies, Inc. annual Operating Income (Loss) for 2021 was -$173M, a 303% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$72.4M +$90M +55.4% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-19
2022 -$162M +$10.8M +6.25% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-19
2021 -$173M -$130M -303% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-28
2020 -$43M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.